Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company whose news flow is driven by clinical trial milestones, regulatory interactions, strategic collaborations, and corporate updates. The company regularly issues press releases detailing progress across a deep pipeline of targeted small molecules and antibody-drug conjugates (ADCs) for molecularly defined solid tumors.
News related to IDYA often highlights developments in its lead program darovasertib, an oral protein kinase C inhibitor in clinical trials for uveal melanoma. Updates include enrollment milestones, progression-free survival and overall survival data from trials such as OptimUM-01 and OptimUM-02 in metastatic uveal melanoma, and neoadjuvant data from OptimUM-09 and the Phase 3 OptimUM-10 trial in primary uveal melanoma. IDEAYA also reports on regulatory designations for darovasertib and its collaboration with Servier for rights outside the United States.
Investors following IDEAYA news will see frequent announcements on its broader pipeline, including IDE397 for MTAP-deleted urothelial cancer and NSCLC, IDE849 for small cell lung cancer and neuroendocrine carcinomas, IDE161 as a PARG inhibitor for ADC combinations, IDE034 as a bispecific B7H3/PTK7 TOP1 ADC, IDE574 as a KAT6/7 dual inhibitor, and IDE892 as a PRMT5 inhibitor. Press releases cover IND submissions and clearances, Phase 1 and Phase 2 data readouts, and plans for upcoming medical conference presentations.
IDYA news also includes financial results, cash runway commentary, licensing transactions such as the Servier darovasertib agreement, and governance or compensation updates reported via SEC filings and corporate press releases. Tracking this news stream provides insight into IDEAYA’s clinical progress, partnering activity, and evolving precision oncology strategy.
Biocytogen and IDEAYA Biosciences have entered into an option and license agreement for a potential first-in-class B7H3/PTK7 bispecific antibody drug conjugate (BsADC) program. The agreement grants IDEAYA an option for an exclusive worldwide license for the program, which targets B7H3/PTK7 co-expression found in multiple solid tumor types. Biocytogen will receive an upfront fee and potential milestone payments totaling $406.5 million, including $100 million in development and regulatory milestones, plus single-digit royalties on net sales.
The BsADC program has the potential to be developed as a monotherapy and in combination with IDEAYA's DNA Damage Repair (DDR) pipeline, including IDE161 (PARG inhibitor). A development candidate nomination is targeted for H2 2024. This collaboration leverages Biocytogen's RenLite® platform and proprietary linker-payload technology to enhance ADC precision and potency.
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in the upcoming 2024 BTIG Virtual Biotechnology Conference. The event is scheduled for Monday, August 5th, 2024 at 10:00 AM ET.
The conference will feature a fireside chat with Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences, hosted by Justin Zelin, Director of Biotechnology Research Analysis at BTIG. This virtual event provides an opportunity for investors to gain insights into IDEAYA's latest developments in targeted therapeutics for oncology.
A live audio webcast of the conference event will be made available through the conference host, allowing interested parties to tune in remotely.
IDEAYA Biosciences (Nasdaq: IDYA) announced the closing of its public offering, including the full exercise of underwriters' option to purchase additional shares. The offering included 8,355,714 common shares at $35.00 each and pre-funded warrants for 285,715 shares at $34.9999 each, generating approximately $302.4 million in gross proceeds. The offering was managed by J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets. The final prospectus is available on the SEC's website.
IDEAYA Biosciences (Nasdaq: IDYA) has announced the pricing for its underwritten public offering of common stock and pre-funded warrants, totaling approximately $263 million in gross proceeds.
The offering includes 7,228,572 shares of common stock at $35.00 per share and 285,715 pre-funded warrants at $34.9999 per warrant. Each pre-funded warrant has an exercise price of $0.0001 per share.
Additionally, underwriters have a 30-day option to purchase up to an extra 1,127,142 shares at the public offering price. The offering is expected to close around July 11, 2024, subject to customary closing conditions.
J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets are serving as joint book-running managers.
IDEAYA Biosciences (Nasdaq: IDYA) has announced a proposed public offering of up to $200 million in common stock and pre-funded warrants.
The company will also grant underwriters a 30-day option to purchase an additional $30 million in common stock.
The offering is subject to market conditions and other factors, with no assurance of completion or specific terms.
J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets are acting as joint book-running managers.
This offering will be conducted under an automatically effective shelf registration statement filed with the SEC, and will be made available via a written prospectus and a prospectus supplement.
IDEAYA Biosciences announced positive interim Phase 2 monotherapy data for IDE397, a potential first-in-class MAT2A inhibitor, in MTAP-deletion urothelial and lung cancer patients. The study showed a 39% overall response rate (ORR) with 1 complete response (CR) and 6 partial responses (PRs). Disease control rate (DCR) was 94%, with 78% of patients exhibiting tumor shrinkage. Notably, 81% of patients experienced over 50% ctDNA reduction. The drug had a favorable safety profile with 5.6% grade 3 or higher adverse events and no serious adverse events. IDE397 is being evaluated for further clinical development in various cancers with MTAP deletions, addressing a significant unmet medical need.
IDEAYA Biosciences will host an investor webcast on July 8, 2024, at 8:00 a.m. EST to report clinical data from the Phase 2 trial of IDE397 monotherapy in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC). IDE397 is a MAT2A inhibitor for MTAP-deletion solid tumors. The agenda includes discussing U.S. incidence rates, patient baseline characteristics, pharmacokinetics, adverse events, clinical efficacy, and molecular response analysis. The webcast will feature CEO Yujiro S. Hata, CMO Darrin Beaupre, and CSO Michael White. Access to the webcast and updated corporate presentation will be provided on the company's website.
IDEAYA Biosciences, a precision medicine oncology company, announced on June 28, 2024, the grant of non-qualified stock options to two newly hired employees. The options, totaling 92,000 shares, were granted under the 2023 Employment Inducement Incentive Award Plan as per Nasdaq Listing Rule 5635(c)(4).
The exercise price is set at $34.37 per share, matching the closing price of IDEAYA's stock on the grant date, June 27, 2024. The options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the commencement date and the rest vesting monthly over the subsequent three years. Vesting is contingent on ongoing employment with IDEAYA.
IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE397, its MAT2A inhibitor, in combination with Gilead's Trodelvy (sacituzumab govitecan-hziy) for treating MTAP-deletion bladder cancer. IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A), while Trodelvy is a Trop-2 directed antibody-drug conjugate. This trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy. MTAP-deletion is present in approximately 26% of bladder cancer patients. IDEAYA and Gilead will retain commercial rights to their respective compounds, and the trial is part of an ongoing IDEAYA-sponsored study. A data update for the IDE397 Phase 2 monotherapy expansion is expected in late 2024.
IDEAYA Biosciences announced updates for its IDE397, a Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors. A clinical data update is anticipated for H2 2024, covering over 15 evaluable MTAP lung and bladder cancer patients, including efficacy and molecular response analyses. The company is expanding IDE397 Phase 2 monotherapy to include bladder cancer, in addition to squamous lung cancer. Over 35 clinical trial sites have been activated globally for rapid enrollment. IDE397 is also involved in a Phase 1/2 trial with Amgen’s AMG 193 and preclinical combinations.